<?xml version='1.0' encoding='utf-8'?>
<document id="22550162"><sentence text="Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature."><entity charOffset="10-22" id="DDI-PubMed.22550162.s1.e0" text="methotrexate" /><entity charOffset="37-47" id="DDI-PubMed.22550162.s1.e1" text="omeprazole" /><entity charOffset="95-107" id="DDI-PubMed.22550162.s1.e2" text="methotrexate" /><entity charOffset="133-145" id="DDI-PubMed.22550162.s1.e3" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e0" e2="DDI-PubMed.22550162.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e0" e2="DDI-PubMed.22550162.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e0" e2="DDI-PubMed.22550162.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e0" e2="DDI-PubMed.22550162.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e1" e2="DDI-PubMed.22550162.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e1" e2="DDI-PubMed.22550162.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e1" e2="DDI-PubMed.22550162.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e2" e2="DDI-PubMed.22550162.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22550162.s1.e2" e2="DDI-PubMed.22550162.s1.e3" /></sentence><sentence text="We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma"><entity charOffset="20-32" id="DDI-PubMed.22550162.s2.e0" text="methotrexate" /><entity charOffset="92-104" id="DDI-PubMed.22550162.s2.e1" text="methotrexate" /><entity charOffset="109-119" id="DDI-PubMed.22550162.s2.e2" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.22550162.s2.e0" e2="DDI-PubMed.22550162.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22550162.s2.e0" e2="DDI-PubMed.22550162.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s2.e0" e2="DDI-PubMed.22550162.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22550162.s2.e1" e2="DDI-PubMed.22550162.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s2.e1" e2="DDI-PubMed.22550162.s2.e2" /></sentence><sentence text=" The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ulcer prophylaxis, and it was discontinued before the start of the first day of the patient's second round of high-dose methotrexate"><entity charOffset="27-37" id="DDI-PubMed.22550162.s3.e0" text="omeprazole" /><entity charOffset="73-85" id="DDI-PubMed.22550162.s3.e1" text="methotrexate" /><entity charOffset="217-229" id="DDI-PubMed.22550162.s3.e2" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.22550162.s3.e0" e2="DDI-PubMed.22550162.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22550162.s3.e0" e2="DDI-PubMed.22550162.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s3.e0" e2="DDI-PubMed.22550162.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22550162.s3.e1" e2="DDI-PubMed.22550162.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22550162.s3.e1" e2="DDI-PubMed.22550162.s3.e2" /></sentence><sentence text=" The 24-hour methotrexate level was elevated and he continued to have sustained levels for 18 days"><entity charOffset="5-25" id="DDI-PubMed.22550162.s4.e0" text="24-hour methotrexate" /></sentence><sentence text=" Side effects due to elevated serum methotrexate included seizures, mucositis, acute renal failure, and thrombocytopenia"><entity charOffset="36-48" id="DDI-PubMed.22550162.s5.e0" text="methotrexate" /></sentence><sentence text=" Aggressive hydration, urinary alkalinization, and leucovorin were continued during the period of elevated methotrexate levels, with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2"><entity charOffset="51-61" id="DDI-PubMed.22550162.s6.e0" text="leucovorin" /><entity charOffset="107-119" id="DDI-PubMed.22550162.s6.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.22550162.s6.e0" e2="DDI-PubMed.22550162.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22550162.s6.e0" e2="DDI-PubMed.22550162.s6.e1" /></sentence><sentence text=" The patient's symptoms resolved, and his renal function returned to baseline within 2 months" /><sentence text=" The patient was able to receive future courses of chemotherapy without methotrexate"><entity charOffset="72-84" id="DDI-PubMed.22550162.s8.e0" text="methotrexate" /></sentence><sentence text=" Although use of the Naranjo adverse reaction probability scale indicated a probable relationship (score of 6) between the patient's development of methotrexate toxicity and omeprazole use, we believe this was a drug-drug interaction case consistent with previous reports in the literature"><entity charOffset="148-160" id="DDI-PubMed.22550162.s9.e0" text="methotrexate" /><entity charOffset="174-184" id="DDI-PubMed.22550162.s9.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.22550162.s9.e0" e2="DDI-PubMed.22550162.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22550162.s9.e0" e2="DDI-PubMed.22550162.s9.e1" /></sentence><sentence text="" /></document>